Please login to the form below
heart attack patients
This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Farxiga scores another FDA fast-track designation
or cardiovascular death in adult following an acute myocardial infarction or heart attack. ... secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.
Latest news
-
AstraZeneca’s Brilinta reduces rate of secondary stroke
heart attack and/or death when given to patients who had previously suffered a stroke or transient transient ischaemic attack. ... The drug is already approved for the treatment of acute coronary syndrome (ACS) and for the secondary prevention of
-
Novartis plans inclisiran trial in the UK
Novartis also plans to conduct ORION-4, the ongoing study for patients who have already had a heart attack or stroke, with this study making the UK the global trial centre. ... In January, Novartis announced that it has teamed up with the NHS which will
-
AZ says Brilinta hits the mark in new stroke trial
When used on its own by patients who had already suffered a stroke or transient ischaemic attack (TIA), it demonstrated a trend towards fewer subsequent events of stroke, heart attack ... The drug is already approved for the treatment of acute coronary
-
Amarin files fish oil-based heart drug Vascepa in Europe
The EU filing comes as Vascepa (icosapent ethyl) is also under review by the FDA for a new label claim that the drug can reduce the incidence of heart attack and ... with Vascepa “major adverse cardiovascular events such as stroke, heart attack and
-
Mistrust of pharma still blocking NHS collaborations
The benefits of well-managed and well-targeted joint working projects to patients and the NHS – and pharma - are widely accepted on both sides, but these remain relatively few and far ... Examples of successful joint initiatives include one between
AstraZeneca’s Brilinta reduces rate of secondary stroke
Novartis plans inclisiran trial in the UK
AZ says Brilinta hits the mark in new stroke trial
Amarin files fish oil-based heart drug Vascepa in Europe
Mistrust of pharma still blocking NHS collaborations
More from news
Approximately 1 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Proving real-world value
Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets
-
Patient collaborations
Published: 21 Nov 2011. AZ’s patient support programme provided holistic support to newly diagnosed heart attack patients. ... Improve discharge information. Maximise adherence to medication. Address psychological health. AstraZeneca also launched a
Proving real-world value
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Understanding the "Big Picture"
In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Future of MHRA uncertain amid Brexit-fuelled shake up
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
- Lucid Group celebrates a double win at Communiqué 2021
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
